Litcius/Paper detail

TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study

Ciarán P. Kelly, Joseph A. Murray, Daniel A. Leffler, Daniel R. Getts, Adam C. Bledsoe, Glennda Smithson, M. Roy First, Amy Morris, Michael S. Boyne, Adam Elhofy, Tsung‐Teh Wu, Joseph R. Podojil, Stephen D. Miller, Robert Fogel, Tobias Freitag, Michele Gerber, Paul K. Haynes, Michael Koren, Mark Matson, Seppo Meri, Thomas H. Oliphant, Barbara Rizzardi, Jocelyn A. Silvester, Mark S. Turner

2021Gastroenterology177 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboGastroenterologyEnteropathyInternal medicineGlutenIntraepithelial lymphocyteCD8Clinical endpointAdverse effectTolerabilityImmunologyImmune systemRandomized controlled trialDiseasePathologyAlternative medicineCeliac Disease Research and ManagementMicroscopic ColitisLiver Diseases and Immunity
TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study | Litcius